Targovax logoTargovax logo

  • About
    About
      • About Targovax
      • Management Team
      • Board of Directors
      • Careers
        • Head of Manufacturing to Targovax
  • Technology
    Technology
      • ONCOS – Oncolyctic Virus
      • Intellectual Property Rights
      • Publications
  • Pipeline
    Pipeline
      • Our pipeline
      • Development Program
        • Melanoma
        • Mesothelioma
        • Collaboration Trials
        • New viruses
  • Partnering
  • Investors & Media
    Investors & Media
      • Our strategy
      • Press releases
      • Capital markets day 2021
      • Financial Reports
      • Presentations
      • Prospectus
      • Debt
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Events
      • Contact
      • Subscribe
  • Governance
    Governance
      • Corporate Governance Policy
      • Corporate Social Responsibility Principles
      • About General Meeting
        • General Meetings
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Articles of Association
  • Contacts
    Contacts
      • Offices
      • Investors & Media
    • About
      • About Targovax
      • Management Team
      • Board of Directors
      • Collaborations
      • Careers
    • Technology
      • ONCOS – Oncolyctic Virus
      • Intellectual Property Rights
      • Publications
    • Pipeline
      • Our pipeline
      • Development program
    • Partnering
      • TG Mutant RAS neoantigen vaccine – Available for partnering
    • Investors & Media
      • Our strategy
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Financial Reports
      • Press releases
      • Presentations
      • Prospectus
      • Debt
      • Events
      • Subscribe
      • Contact
    • Governance
      • Corporate Governance Report
      • Corporate Social Responsibility Principles
      • About General Meeting
        • General Meetings
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Articles of Association
    • Contacts
      • Offices
      • Career
      • Investors & Media
    Share price
    Share price

    Financial Reports

    2020
    • 2021
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • All years
    Type of information
    • Annual Reports
    • Interim Reports
      Report Presentation Webcast Other
    February 18, 2021 Annual report 2020
    February 18, 2021 Q4 Fourth Quarter
    November 5, 2020 Q3 Third Quarter
    August 20, 2020 Q2 Second Quarter
    May 7, 2020 Q1 First Quarter
    IR contact
    Torbjørn Furuseth
    Torbjørn Furuseth
    CFO
    torbjorn.furuseth@targovax.com
    +47 932 11 101
    Renate Birkeli
    Renate Birkeli
    Investor Relations
    renate.birkeli@targovax.com
    +47 922 61 624

    Q1 First quarter 2021

    Targovax ASA announced its first quarter 2021 results on Thursday 6 May 2021. An online presentation by Targovax’s management to investors, analysts and the press took place the same day at 10:00 am CEST.

     

    • Report
    • Presentation
    • Webcast
    Read the report

    Subscribe

    Read more about our Protection of your personal data.

    Share

    • PRINT
    • STAY CONNECTED
    • Terms of use
    • Privacy policy

    This website uses cookies to ensure you get the best experience on our website. Learn More | Terms of Use

    Yes, I accept